Caplight Directory>Companies>Delix Therapeutics-preview>Delix


Delix Therapeutics

Delix Therapeutics

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://www.delixtherapeutics.com

Last Round

Strategic

Sep 10, 2025

Total Funding Raised

$126.2M

Momentum Score

25 /100

Company Overview

Delix is a biotechnology company focused on developing clinical-stage neuroscience therapeutics that leverage innovative neuroplasticity-promoting treatments for challenging neuropsychiatric and neurological disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Mental Health, Clinical Trials

Business Model

B2G

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

psychoplastogensneuroplastogensnon-hallucinogenic psychedelicsneuroplasticitypsychedelic analogsclinical-stage biotechdrug discoverydepression treatmentsmall-molecule drugsCNS disorderstake-home medicinemental health therapeuticssubstance use disorderdrug discovery platformPTSD treatment

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Delix Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Delix Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
StrategicSep 10, 2025
GrantJun 4, 2024
GrantDec 13, 2023
DebtJan 10, 2022
Convertible DebtJan 10, 2022
Series A
Sep 27, 2021
View all Funding Rounds

Key People

Founding team and executive leadership

Mark Rus

Chief Executive Officer Director

Executive Team

Tricia McCall

Chief People Officer (CPO)

Executive Team

Delix Therapeutics Investors

Notable investors and investment history

InvestorRounds
Casa Verde CapitalSeries A
RA Capital ManagementSeries A
Dolby Family VenturesSeries A
U.S. Department of DefenseGrant
NIH RADxGrant
ARTIS VenturesSeries A
re.Mind CapitalSeries A
View all Investors

Delix Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Delix Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Delix Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range25
Year Founded2019
Last FundingSep 10, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.